Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Benedetti, F. Articles by Smeraldi, E. Search for Related Content PubMed Citation Articles by Benedetti, F. Articles by Smeraldi, E. Impulse Control Disorders Depression

Fluvoxamine Treatment of Major Depression Associated With Multiple Sclerosis

Received September 12, 2002; revised December 15, 2002; accepted January 13, 2003. From the Università Vita-Salute San Raffaele, School of Medicine. Department of Neuropsychiatric Sciences. Milano. Address correspondence to Dr. Benedetti, Istituto Scientifico Ospedale San Raffaele, Department of Neuropsychiatric Sciences, Via Stamira d'Ancona 20, 20127 Milano, Italy; benedetti.francesco{at}hsr.it (E-mail).

ABSTRACT

Fluvoxamine 200 mg was administered for 3 months to a group of 43 interferon ß-1b treated patients affected by major depression associated with multiple sclerosis. Despite a 16.3% attrition rate, 79% of patients achieved response. The drug was well tolerated.

This article has been cited by other articles:

				S. Patten, J. Williams, and L. Metz Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 406 - 411. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2004 American Neuropsychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us